000182177 001__ 182177
000182177 005__ 20240229145712.0
000182177 0247_ $$2doi$$a10.1038/s41541-022-00539-0
000182177 0247_ $$2pmid$$apmid:36216845
000182177 0247_ $$2pmc$$apmc:PMC9550855
000182177 0247_ $$2altmetric$$aaltmetric:136979803
000182177 037__ $$aDKFZ-2022-02479
000182177 041__ $$aEnglish
000182177 082__ $$a610
000182177 1001_ $$00000-0001-6624-4524$$aMariz, Filipe Colaco$$b0$$eFirst author
000182177 245__ $$aA broadly protective vaccine against cutaneous human papillomaviruses.
000182177 260__ $$a[London]$$bNature Publishing Group$$c2022
000182177 3367_ $$2DRIVER$$aarticle
000182177 3367_ $$2DataCite$$aOutput Types/Journal article
000182177 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1666356504_20555
000182177 3367_ $$2BibTeX$$aARTICLE
000182177 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000182177 3367_ $$00$$2EndNote$$aJournal Article
000182177 500__ $$a#EA:F035#LA:F035#
000182177 520__ $$aSkin colonization by human papillomavirus (HPV) is typically related to inconspicuous cutaneous infections without major disease or complications in immunocompetent individuals. However, in immunosuppressed patients, especially organ transplanted recipients, cutaneous HPV infections may cause massive, highly spreading and recurrent skin lesions upon synergism with UV-exposure. Current HPV prophylactic vaccines are not effective against cutaneous HPV types (cHPV). By applying a modular polytope-based approach, in this work, we explored different vaccine candidates based on selected, tandemly arranged cHPV-L2 epitopes fused to thioredoxin (Trx) as a scaffold protein. Upon conversion to heptameric nanoparticles with the use of a genetically fused oligomerization domain, our candidate Trx-L2 vaccines induce broadly neutralizing immune responses against 19 cHPV in guinea pigs. Similar findings were obtained in mice, where protection against virus challenge was also achieved via passive transfer of immune sera. Remarkably, immunization with the candidate cHPV vaccines also induced immune responses against several mucosal low- and high-risk HPV types, including HPV16 and 18. Based on cumulative immunogenicity data but also on ease and yield of production, we identified a lead vaccine candidate bearing 12 different cHPV-L2 epitopes that holds great promise as a scalable and GMP production-compatible lead molecule for the prevention of post-transplantation skin lesions caused by cHPV infection.
000182177 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000182177 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000182177 7001_ $$0P:(DE-He78)db1ba71c5c64931f43e2495fa14a5ebe$$aBalz, Kathrin$$b1
000182177 7001_ $$0P:(DE-He78)2e775c37c530c612fc6f82cc05022305$$aDittrich, Manuela$$b2$$udkfz
000182177 7001_ $$0P:(DE-He78)35b8b312f24f786ff12489e8b1cf05ee$$aZhang, Yueru$$b3$$udkfz
000182177 7001_ $$0P:(DE-He78)d53df92888ab12d6bb3ce767d044e53f$$aYang, Fan$$b4
000182177 7001_ $$0P:(DE-He78)2d5634b584ebede249368464b907e28c$$aZhao, Xueer$$b5$$udkfz
000182177 7001_ $$aBolchi, Angelo$$b6
000182177 7001_ $$aOttonello, Simone$$b7
000182177 7001_ $$0P:(DE-He78)4cbf38280ce272e37f96081b070dd46a$$aMüller, Martin$$b8$$udkfz
000182177 773__ $$0PERI:(DE-600)2882262-6$$a10.1038/s41541-022-00539-0$$gVol. 7, no. 1, p. 116$$n1$$p116$$tnpj vaccines$$v7$$x2059-0105$$y2022
000182177 909CO $$ooai:inrepo02.dkfz.de:182177$$pVDB
000182177 9101_ $$0I:(DE-588b)2036810-0$$60000-0001-6624-4524$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000182177 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)db1ba71c5c64931f43e2495fa14a5ebe$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000182177 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2e775c37c530c612fc6f82cc05022305$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000182177 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)35b8b312f24f786ff12489e8b1cf05ee$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000182177 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d53df92888ab12d6bb3ce767d044e53f$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000182177 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2d5634b584ebede249368464b907e28c$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000182177 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4cbf38280ce272e37f96081b070dd46a$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000182177 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000182177 9141_ $$y2022
000182177 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000182177 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000182177 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-05-04
000182177 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000182177 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000182177 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000182177 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNPJ VACCINES : 2021$$d2022-11-17
000182177 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-17
000182177 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-17
000182177 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-10-13T14:41:50Z
000182177 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-10-13T14:41:50Z
000182177 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-10-13T14:41:50Z
000182177 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-17
000182177 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-17
000182177 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-17
000182177 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNPJ VACCINES : 2021$$d2022-11-17
000182177 9202_ $$0I:(DE-He78)F035-20160331$$kF035$$lF035 Tumorvirus-spez. Vakzinierungsstrategie$$x0
000182177 9200_ $$0I:(DE-He78)F035-20160331$$kF035$$lF035 Tumorvirus-spez. Vakzinierungsstrategie$$x0
000182177 9201_ $$0I:(DE-He78)F035-20160331$$kF035$$lF035 Tumorvirus-spez. Vakzinierungsstrategie$$x0
000182177 980__ $$ajournal
000182177 980__ $$aVDB
000182177 980__ $$aI:(DE-He78)F035-20160331
000182177 980__ $$aUNRESTRICTED